Monteris Medical Secures $63M for Neurosurgery Expansion: NeuroBlate System Poised for Growth
March 13, 2026, 9:56 am
Monteris Medical secured $63M across Series E equity and debt financing. This capital fuels aggressive expansion for its NeuroBlate System. The technology offers minimally invasive, robotically controlled laser brain surgery for tumors and epilepsy. It aims to revolutionize neurosurgical treatment with unparalleled precision and significantly reduced recovery times. Funds will accelerate vital U.S. commercial growth, bolster clinical research, and extend global reach for this innovative MedTech solution. This strategic investment positions Monteris for leadership in advanced neurosurgical care.
Monteris Medical, a leading neurosurgery company, has announced a significant capital raise. The Minnetonka, MN-based firm secured a total of $63 million. This strategic infusion comprises $28 million in Series E equity funding and a new $35 million credit facility. This substantial investment bolsters the company's financial foundation. It will drive aggressive expansion of its pioneering neurosurgical technology.
The Series E funding round saw robust participation. InnovaHealth Partners and Birchview Capital, LP led the investment. New investors also joined, including OSF Ventures, OSF HealthCare, and the Colorado University Healthcare Innovation Fund. These commitments highlight strong confidence in Monteris Medical's vision. They validate the impact of its innovative solutions.
Trinity Capital, a prominent alternative asset manager, provided the $35 million growth capital. This debt financing establishes a new credit facility for Monteris Medical. It also allowed for refinancing of existing debt. Trinity Capital's involvement signals strong belief in the company’s growth trajectory. This partnership underscores the increasing demand for advanced medical technologies.
Monteris Medical develops and markets the NeuroBlate System. This MR-guided laser ablation system enables minimally invasive brain surgery. It is a robotically controlled platform. Surgeons use it for precise laser interstitial thermal therapy (LITT). The technology is also known as stereotactic laser ablation (SLA).
The NeuroBlate System represents a significant advancement in neurosurgery. It precisely destroys abnormal brain tissue. This includes certain brain tumors. It also targets specific areas of the brain causing seizures from epilepsy. The system operates with exceptional accuracy. It minimizes disruption to surrounding healthy brain structures.
This technology offers critical benefits over traditional open brain surgery. It is a minimally invasive alternative. Patients experience reduced complications. Hospital stays are often shortened. Recovery times can be faster. These advantages translate to improved patient outcomes.
A key feature of the NeuroBlate System is its robotic interface. This interface supports targeted and safe delivery of laser energy. It is the only LITT platform offering this robotic control. This precise control enhances procedural safety and efficacy. It gives surgeons greater confidence during delicate operations.
Clinical evidence supports the NeuroBlate System's effectiveness. Published prospective clinical data demonstrates its benefits. This data provides a strong foundation for its widespread adoption. Nearly 130 health systems across North America currently utilize the NeuroBlate System. It serves both adults and children aged two and older.
The newly secured funds will fuel several critical initiatives. A primary focus is expanding Monteris Medical's U.S. commercial footprint. This involves increasing sales and market penetration. More hospitals and neuroscience centers will gain access to this transformative technology.
Further growth initiatives are also underway. The company plans accelerated investment in technology development. This will lead to new product innovations. Enhancements to the NeuroBlate System are expected. These advancements will further improve patient care.
Clinical research programs will also expand. Robust research ensures continuous improvement and validation. It also explores new applications for the NeuroBlate System. This commitment to research solidifies Monteris Medical's leadership in the field.
Geographic expansion forms another key pillar of the strategy. Monteris Medical aims to bring its technology to more patients worldwide. Broader access to minimally invasive neurosurgery will benefit global healthcare. This outreach underscores the company's mission.
The capital will specifically support the commercialization of the NeuroBlate System. This includes marketing efforts and sales force expansion. It will accelerate adoption across leading neuroscience centers. Monteris Medical is committed to making this technology widely available.
This funding round reflects strong investor confidence. It signals belief in Monteris Medical’s strategy. Investors recognize the expanding clinical impact of the NeuroBlate System. The company's innovative approach advances the life sciences sector. It expands treatment options in neurosurgery.
Monteris Medical is pushing boundaries in medical technology. Its solutions deliver meaningful new treatment options for patients. The company's leadership remains focused on innovation. It prioritizes patient-centric solutions. This funding ensures continued investment in these critical areas.
The market for minimally invasive neurosurgical solutions is growing. Patients and providers increasingly seek less intrusive procedures. The NeuroBlate System perfectly aligns with this trend. It offers a sophisticated, precise, and less disruptive alternative.
This financial boost allows Monteris Medical to maintain its trajectory. It will continue delivering innovative solutions. The company's future looks promising. Its impact on neurosurgical care is set to grow significantly.
Monteris Medical, a leading neurosurgery company, has announced a significant capital raise. The Minnetonka, MN-based firm secured a total of $63 million. This strategic infusion comprises $28 million in Series E equity funding and a new $35 million credit facility. This substantial investment bolsters the company's financial foundation. It will drive aggressive expansion of its pioneering neurosurgical technology.
The Series E funding round saw robust participation. InnovaHealth Partners and Birchview Capital, LP led the investment. New investors also joined, including OSF Ventures, OSF HealthCare, and the Colorado University Healthcare Innovation Fund. These commitments highlight strong confidence in Monteris Medical's vision. They validate the impact of its innovative solutions.
Trinity Capital, a prominent alternative asset manager, provided the $35 million growth capital. This debt financing establishes a new credit facility for Monteris Medical. It also allowed for refinancing of existing debt. Trinity Capital's involvement signals strong belief in the company’s growth trajectory. This partnership underscores the increasing demand for advanced medical technologies.
Monteris Medical develops and markets the NeuroBlate System. This MR-guided laser ablation system enables minimally invasive brain surgery. It is a robotically controlled platform. Surgeons use it for precise laser interstitial thermal therapy (LITT). The technology is also known as stereotactic laser ablation (SLA).
The NeuroBlate System represents a significant advancement in neurosurgery. It precisely destroys abnormal brain tissue. This includes certain brain tumors. It also targets specific areas of the brain causing seizures from epilepsy. The system operates with exceptional accuracy. It minimizes disruption to surrounding healthy brain structures.
This technology offers critical benefits over traditional open brain surgery. It is a minimally invasive alternative. Patients experience reduced complications. Hospital stays are often shortened. Recovery times can be faster. These advantages translate to improved patient outcomes.
A key feature of the NeuroBlate System is its robotic interface. This interface supports targeted and safe delivery of laser energy. It is the only LITT platform offering this robotic control. This precise control enhances procedural safety and efficacy. It gives surgeons greater confidence during delicate operations.
Clinical evidence supports the NeuroBlate System's effectiveness. Published prospective clinical data demonstrates its benefits. This data provides a strong foundation for its widespread adoption. Nearly 130 health systems across North America currently utilize the NeuroBlate System. It serves both adults and children aged two and older.
The newly secured funds will fuel several critical initiatives. A primary focus is expanding Monteris Medical's U.S. commercial footprint. This involves increasing sales and market penetration. More hospitals and neuroscience centers will gain access to this transformative technology.
Further growth initiatives are also underway. The company plans accelerated investment in technology development. This will lead to new product innovations. Enhancements to the NeuroBlate System are expected. These advancements will further improve patient care.
Clinical research programs will also expand. Robust research ensures continuous improvement and validation. It also explores new applications for the NeuroBlate System. This commitment to research solidifies Monteris Medical's leadership in the field.
Geographic expansion forms another key pillar of the strategy. Monteris Medical aims to bring its technology to more patients worldwide. Broader access to minimally invasive neurosurgery will benefit global healthcare. This outreach underscores the company's mission.
The capital will specifically support the commercialization of the NeuroBlate System. This includes marketing efforts and sales force expansion. It will accelerate adoption across leading neuroscience centers. Monteris Medical is committed to making this technology widely available.
This funding round reflects strong investor confidence. It signals belief in Monteris Medical’s strategy. Investors recognize the expanding clinical impact of the NeuroBlate System. The company's innovative approach advances the life sciences sector. It expands treatment options in neurosurgery.
Monteris Medical is pushing boundaries in medical technology. Its solutions deliver meaningful new treatment options for patients. The company's leadership remains focused on innovation. It prioritizes patient-centric solutions. This funding ensures continued investment in these critical areas.
The market for minimally invasive neurosurgical solutions is growing. Patients and providers increasingly seek less intrusive procedures. The NeuroBlate System perfectly aligns with this trend. It offers a sophisticated, precise, and less disruptive alternative.
This financial boost allows Monteris Medical to maintain its trajectory. It will continue delivering innovative solutions. The company's future looks promising. Its impact on neurosurgical care is set to grow significantly.